A new study led by researchers at the Montreal Neurological Institute and Hospital of ÁùºÏ²Ê¿ª½±½á¹û and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis...
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary...
The Montreal Neurological Institute and Hospital – The Neuro at ÁùºÏ²Ê¿ª½±½á¹û and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments...
A new study led by researchers at the Montreal Neurological Institute and Hospital of ÁùºÏ²Ê¿ª½±½á¹û and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis...